Please ensure Javascript is enabled for purposes of website accessibility
Cheryl Swanson

Cheryl Swanson


Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson

Recent articles


Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?

Gilead's HIV preventing med is not only groundbreaking, it could be the cure to what ails this stock.


3 Great Dividend Stocks with a Clearance Sale Going on Now

These great stocks offer excellent yields, exceptional growth, and are terrific bargains.


3 Biotechs With Save-the-Date Catalysts on Tap

Kite Pharma, bluebird bio, and ACADIA Pharmaceuticals all have price-shaking catalysts approaching that could bring big profits to investors.


Why UnitedHealth Is the Only Healthcare Insurer to Own

With the Affordable Care Act's future in jeopardy, the insurance stock you want to own is the only one with zero exposure to the ACA: UnitedHealth.


You'll Never Guess Who Owns the Most Spectacular New Cancer Drug

Johnson & Johnson's new cancer treatment isn't just a drug; it's a $5 billion breakthrough.


Is Pfizer Rethinking a Company Spin-Off?

A $14 billion spin-off of its over-the-counter drug unit would be great news for investors -- but will it happen?


3 Stocks Set to Thrive in Pharma's New Price-Conscious World

Worried about the election's impact on pharma? Protect yourself with three great stocks relying on innovation, not price increases, for growth


$10 Billion Flop: Is Amgen Stock Still a Buy?

With Amgen facing declining demand for its blockbusters, as well as a key failure with its $10 billion pipeline molecule, is this biotech worth buying?

skull and crossbones made of pills drugs poison toxic warning

Unfazed by FDA Warning, Gilead Sciences' Stock Could Be Turning a Corner

Look past the scary headlines, and you may see a comeback in store for Gilead's investors.


No Cure Yet for Breast Cancer, but 3 Big Advances in 2016

Here’s how an exciting wave of recent discoveries is moving us closer to a cure.


7 Reasons Celgene Is the Best Bet in Biotech

Here’s how Celgene plans to rack up double-digit growth for decades to come.


3 Cardiac-Care Stocks That Could Bring Heart-Stopping Gains

Investors hit the jackpot with cardiac-care stocks last year. Here are three stocks primed to continue the heart-stopping gains.


Tesaro Inc. Is Flying High Today (and Could Go Higher From Here)

Here's why cancer biotech Tesaro could be in the midst of a new lift-off.


3 Reasons Pfizer's Recent Drop Could Make It a Buying Opportunity

This stock is back in the game with a pipeline full of near-term catalysts, superstar oncology drugs, and a 3.5% dividend yield.


Is Celgene the Smartest Buyer in Biotech?

Celgene’s deal-making genius tilts the odds in favor of its investors.


How Oncology Could Move the Needle for Johnson & Johnson's Stock

Johnson & Johnson has some oncology drug surprises up its sleeves that could drive further upside for this great stock.


Why Johnson & Johnson's New Wearable for Diabetics Should Be a Home Run

Johnson & Johnson is launching a wearable that boldly embraces the huge diabetes market -- and could reignite its lagging medical-devices division.


3 Biotechs With Potential Big-Time Upside

These three high-risk/high-reward biotechs have drugs in late-stage trials and key catalysts just around the corner.


Apple iPhone Calling Big Pharma: We Can Help You Develop Better Drugs

Apple is moving deeper into healthcare -- and big pharma is answering the call.


Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data

The two biotechs are closing in on explosive potential catalysts, including FDA filings and hoped-for approvals, but thin data could bring nasty surprises for investors.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.